You are here: Industry Insights > peanut allergy

News List

Study shows psychosocial effects of peanut allergy pharmatimes
February 10, 2022
Research demonstrates that people who live with peanut allergies face isolation and discrimination.
European Commission approves first treatment for peanut allergy europeanpharmaceuticalreview
January 06, 2021
Aimmune Therapeutics’ PALFORZIA® has been approved by the European Commission as a treatment for peanut allergy.
Aimmune’s peanut allergy med Palforzia wins EU approval pharmatimes
December 22, 2020
The European Commission (EC) has approved Aimmune Therapeutics’ Palforzia, making it the first treatment for peanut allergy in the EU, according to the firm.
Aimmune’s peanut allergy med moves toward EU approval pharmatimes
October 22, 2020
Aimmune has been granted a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for its drug Palforzia as a treatment of peanut allergic patients aged 4-17 years.
Phase III results move Aimmune’s peanut allergy drug closer to EU market pharmatimes
March 28, 2019
Aimmune has announced the results from its Phase III European clinical trials for AR101, the company’s investigational oral biologic drug designed to help protect patients from severe allergic reactions in case they are accidentally exposed to peanut.
FDA delays review of peanut allergy drug amid Trump shutdown pharmaphorum
January 17, 2019
One of the first pharma victims of the current partial shutdown of the US government has emerged after the FDA said it would delay a review of a peanut allergy drug from Aimmune Therapeutics.
DBV CMO leaves as peanut allergy player rejigs team in wake of BLA withdrawal fiercebiotech
January 07, 2019
Lucia Septién-Velez has stepped down (PDF) as chief medical officer of DBV Technologies. The departure of Septién-Velez is part of a wider reshuffle that gives DBV’s management a new look as it seeks to get its BLA back on track.....
DBV pulls peanut allergy filing after FDA faults data details fiercebiotech
December 25, 2018
DBV Technologies has withdrawn the filing for FDA approval of its peanut allergy therapy. The French biotech pulled the BLA after talks with the agency revealed gaps in the manufacturing and quality-control sections of the filing....
Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 4–17 drugs
December 24, 2018
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has submitted a ....
Aimmune publishes phase III data for peanut allergy drug pharmaceutical
November 21, 2018
Aimmune has published the data from its phase III PALISADE clinical trial into AR101, a biologic immunotherapy indicated for desensitisation of patients with peanut allergies in the New England Journal of Medicine.